ClinicalTrials.gg
CompletedNCT07616635FOVOCIPUpdated Jun 1, 2026

A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia (FOVOCIP)

A Phase 3 interventional study of Fosfomycin and ciprofloxacin in Haematopoietic Stem Cell Transplantation and Acute Leukemia, sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 4 years 1 month after the study started (first participant enrolled Mar 2022, registered May 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Prophylaxis with fluoroquinolones in high-risk neutropenic patients is currently under scrutiny due to their toxicity and the potential of selecting multirresistant bacteria. In this setting, the search for an alternative prophylactic drug is a priority. The FOVOCIP study aimed to evaluate the efficacy and safety of fosfomycin compared to ciprofloxacin in this population. This was a multicentre, randomised, phase-3, non-inferiority, open-label trial performed in 11 centres in Spain. Adults diagnosed with acute leukaemia or recipients of a Haematopoietic Stem Cell Transplant were randomised to receive oral fosfomycin or oral ciprofloxacin as prophylaxis. The primary endpoint was rate of febrile neutropenia. Secondary endpoints included safety, including microbiological safety and gut microbiota changes .

02

Conditions studied

  • Haematopoietic Stem Cell Transplantation
  • Acute Leukemia
03

In context

Lead sponsor

Fundación para la Investigación Biosanitaria del Principado de Asturias is the lead sponsor of 13 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Subjects must be able to understand the study procedures, comply with them, and provide written prior to any specific study procedures.
  2. Adult subjects ≥ 18 years of age diagnosed with acute leukaemia who are scheduled to receive a first course of intensive chemotherapy.
  3. Adult subjects ≥ 18 years of age who are candidates for a first haematopoietic stem cell transplant with myeloablative conditioning or adult subjects ≥ 18 years of age who are candidates for a first allogeneic haematopoietic stem cell transplant with reduced-intensity conditioning or an autologous haematopoietic stem cell transplant, provided that at least one of the following risk factors for infection is present:

    1. Functional status (, ECOG) ≥2.
    2. Expected grade 3-4 mucositis.
    3. Age ≥65 years.
    4. Comorbidity index (HCTI) ≥3.
    5. Serum albumin \< 35 g/L.
    6. Active or neoplasia at the time of stem cell transplantation.
    7. Total dose of etoposide > 500 mg/m2.
    8. Total dose of cytarabine > 1 g/m2.
  4. Functional status (Eastern Cooperative Oncology Group, ECOG) from 0 to 3.
  5. Adequate organ function defined as:

    • Liver: , alkaline phosphatase or \< 3 times the upper normal limit (unless attributable to tumour activity).
    • Renal: creatinine ≤ 250 μmol/l (2.5 mg/dL) (unless attributable to leukemic infiltration).
  6. greater than 3 months.
  7. Women of childbearing age must not be pregnant or breastfeeding and must have a negative pregnancy test at the time of screening. Women of childbearing age and men with female partners of childbearing age must commit to using two highly effective forms of and must agree not to become pregnant or father a child while receiving any study therapy and for at least 3 months after completing treatment.

Exclusion criteria

Patients who meet any of the following exclusion criteria will not be eligible for inclusion in this study:

  1. to fluoroquinolones or fosfomycin.
  2. Treatment with broad-spectrum antimicrobial therapy within 4 weeks of the first study treatment.
  3. Intensive chemotherapy or previous haematopoietic stem cell transplantation. Treatment with hydroxyurea or used to control white blood cell count is permitted.
  4. Fever of infectious origin or documented infection within 4 weeks of the first study treatment.
  5. Presence of any serious psychiatric illness or physical condition that, in the opinion of the physicians, contraindicates the patient's inclusion in the clinical trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
177 participants (actual)

Study arms

  • Active comparator
    Standard prophylaxis

    Drug: ciprofloxacin

  • Experimental
    Alternative prophilaxis

    500 mg three times a day

    Drug: Fosfomycin

Interventions

06

What researchers measure

Primary outcomes

  1. Febrile neutropenia

    Fever was defined as a single oral temperature of 38.3 °C or a temperature of 38 °C sustained over a 1-h period. If the patient was receiving any medication with a high probability of inducing fever or had been previously transfused, at least a positive culture or an infected site was required to be ascribed to infection.

    Time frame: The primary endpoint will be evaluated from the first day of chemotherapy until the absolute neutrophil count has reached >0.5x109/L, for a maximum of 60 days in case ANC >0.5x109/L is not reached.

07

Study locations

1 site
  • Hospital Universitario Central de Asturias
    Oviedo, Principality of Asturias 33011, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in May 2024, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
Jun 1, 2026
StartActual
Mar 14, 2022
Primary completionActual
May 29, 2024
CompletionActual
Dec 1, 2024
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07616635
Lead sponsor
Fundación para la Investigación Biosanitaria del Principado de Asturias
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Mar 14, 2022
Primary completion
May 29, 2024
Completion
Dec 1, 2024
Last update
Jun 1, 2026

Study contacts

Teresa Bernal, MD OHD
principal investigator · Universidad de Oviedo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosfomycin

Start the discussion